Skip to main content

MW 445 Da, Purity >99%. Potent and selective CCR1 antagonist (IC50 = 8.4 μM). Ki values are 0.04 nM (CCR1) and >10 nM (CCR5, CXCR2 and CXCR4). Displays inverse agonist activity for US28, a HCMV-encoded receptor. Able to produce concentration-dependent inhibition of MIP-1α and Ca2+ mobilization.

Be the first to review this product! Submit a review

Images

Chemical Structure - BX 513 hydrochloride, CCR1 antagonist (AB120811), expandable thumbnail

Key facts

Purity
> 99%
Form
Solid
Molecular weight
445 Da
Molecular formula
C28H29ClN2O
PubChem identifier
9889700
Nature
Synthetic

Alternative names

Recommended products

MW 445 Da, Purity >99%. Potent and selective CCR1 antagonist (IC50 = 8.4 μM). Ki values are 0.04 nM (CCR1) and >10 nM (CCR5, CXCR2 and CXCR4). Displays inverse agonist activity for US28, a HCMV-encoded receptor. Able to produce concentration-dependent inhibition of MIP-1α and Ca2+ mobilization.

Key facts

Purity
> 99%
PubChem identifier
9889700
Solubility

Soluble in DMSO to 100 mM.

Soluble in ethanol to 50 mM.

Biochemical name
5-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-2,2-diphenyl-pentanenitrile
Biological description

Potent and selective CCR1 antagonist (IC50 = 8.4 μM). Ki values are 0.04 nM (CCR1) and >10 nM (CCR5, CXCR2 and CXCR4). Displays inverse agonist activity for US28, a HCMV-encoded receptor. Able to produce concentration-dependent inhibition of MIP-1α and Ca2+ mobilization.

Canonical SMILES
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(C#N)(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChI=1S/C28H29ClN2O/c29-26-14-12-25(13-15-26)28(32)17-20-31(21-18-28)19-7-16-27(22-30,23-8-3-1-4-9-23)24-10-5-2-6-11-24/h1-6,8-15,32H,7,16-21H2
InChIKey
MEEJEEVTIVAOJP-UHFFFAOYSA-N
IUPAC name
5-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-2,2-diphenylpentanenitrile

Storage

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Store under desiccating conditions, The product can be stored for up to 12 months

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

CCR3 (C-C chemokine receptor type 3) and CCR1 (C-C chemokine receptor type 1) belong to the chemokine receptor family which act as signaling proteins involved in immune responses. The CCR3 receptor has an approximate mass of 41 kDa while CCR1 is around 42 kDa. These receptors are expressed on various immune cells such as eosinophils and basophils. The dopamine D2 receptor also known as DRD2 has a mass of approximately 50 kDa and is expressed mainly in the central nervous system particularly in dopaminergic neurons. All three play significant roles through G-protein coupled receptor (GPCR) mechanisms.

Biological function summary

The CCR3 receptor mediates the migration and activation of inflammatory cells heavily involved in allergic responses. CCR1 also facilitates cell movement and acts in inflammatory processes often working in conjunction with chemokines such as CCL5. The dopamine D2 receptor influences neurotransmission and plays critical roles in modulating physiological functions like locomotion and behavior. While unrelated in function these proteins act through receptor complexes involving second messengers to relay signals inside cells.

Pathways

CCR3 participates in the chemokine signaling pathway integral for directing cell traffic and maintaining tissue homeostasis. It interacts with proteins like CXCR4 in immune regulation. CCR1 also engages in chemokine signaling having significant interactions within inflammatory pathways. The dopamine D2 receptor is a part of dopaminergic signaling pathways and interacts closely with proteins like G-proteins particularly influencing the cyclic AMP production in neurons.

Associated diseases and disorders

CCR3 and CCR1 connect to conditions like asthma and rheumatoid arthritis where inflammatory mechanisms are prominent. CCR3 is linked with eosinophilic inflammation in asthma. The dopamine D2 receptor is associated with neurological disorders such as schizophrenia and Parkinson's disease where dopaminergic regulation is disrupted. Through shared pathways CCR3 CCR1 and DRD2 align with various other proteins influencing disease progression and treatment strategies.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

1 product image

  • Chemical Structure - BX 513 hydrochloride, CCR1 antagonist (ab120811), expandable thumbnail

    Chemical Structure - BX 513 hydrochloride, CCR1 antagonist (ab120811)

    2D chemical structure image of ab120811, BX 513 hydrochloride, CCR1 antagonist

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com